Yangsong Wang

Yangsong Wang

Auto-generated profile, based on publicly available information

Yangsong Wang

Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
MKMotoko Kimura
Motoko Kimura
MKMasahiro Kiuchi
Masahiro Kiuchi
AAAmi Aoki
Ami Aoki
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
Tumor-specific CD8+ T cells play a pivotal role in antitumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stemlike CD8+ T cells give rise to their cytotoxic progeny—Tim-3+ terminally differentiated CD8+ T cells. However, where and how this differentiation process occurs has not been elucidated. We herein show that terminally differentiated CD8+ T cells can be generated within tumor-draining lymph nodes (TDLN) and that CD69 expression on tumor-specific CD8+ T cells controls its differentiation process through regulating the expression of the transcription factor TOX. In TDLNs, CD69 deficiency diminished TOX expression in tumor-specific CD8+ T cells, and consequently promoted generation of functional terminally differentiated CD8+ T cells. Anti-CD69 administration promoted the generation of terminally differentiated CD8+ T cells, and the combined use of anti-CD69 and anti–programmed cell death protein 1 (PD-1) showed an efficient antitumor effect. Thus, CD69 is an attractive target for cancer immunotherapy that synergizes with immune checkpoint blockade.

22 November 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMurshed H. Sarkar
Murshed H. Sarkar
RYRyoji Yagi
Ryoji Yagi
YEYukihiro Endo
Yukihiro Endo
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
While IFNγ is a well-known cytokine that actively promotes the type I immune response, it is also known to suppress the type II response by inhibiting the differentiation and proliferation of Th2 cells. However, the mechanism by which IFNγ suppresses Th2 cell proliferation is still not fully understood. We found that IFNγ decreases the expression of growth factor independent-1 transcriptional repressor (GFI1) in Th2 cells, resulting in the inhibition of Th2 cell proliferation. The deletion of theGfi1gene in Th2 cells results in the failure of their proliferation, accompanied by an impaired cell cycle progression. In contrast, the enforced expression of GFI1 restores the defective Th2 cell proliferation, even in the presence of IFNγ. These results demonstrate that GFI1 is a key molecule in the IFNγ-mediated inhibition of Th2 cell proliferation.

24 July 2026 in Science Advances
Verified
Journal Article
Closed access
YWYangsong Wang
Yangsong Wang
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
YEYukihiro Endo
Yukihiro Endo
IHIchita Hasegawa
Ichita Hasegawa
AOAtsushi Onodera
Atsushi Onodera
MKMotoko Kimura
Motoko Kimura
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.

26 November 2025
Verified
Other
Open access
PDF file
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
MKMotoko Kimura
Motoko Kimura
MKMasahiro Kiuchi
Masahiro Kiuchi
AAAmi Aoki
Ami Aoki
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11

3 August 2023
Verified
Other
Open access
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
MKMotoko Kimura
Motoko Kimura
MKMasahiro Kiuchi
Masahiro Kiuchi
AAAmi Aoki
Ami Aoki
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
Tumor-specific CD8+ T cells play a pivotal role in antitumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stemlike CD8+ T cells give rise to their cytotoxic progeny—Tim-3+ terminally differentiated CD8+ T cells. However, where and how this differentiation process occurs has not been elucidated. We herein show that terminally differentiated CD8+ T cells can be generated within tumor-draining lymph nodes (TDLN) and that CD69 expression on tumor-specific CD8+ T cells controls its differentiation process through regulating the expression of the transcription factor TOX. In TDLNs, CD69 deficiency diminished TOX expression in tumor-specific CD8+ T cells, and consequently promoted generation of functional terminally differentiated CD8+ T cells. Anti-CD69 administration promoted the generation of terminally differentiated CD8+ T cells, and the combined use of anti-CD69 and anti–programmed cell death protein 1 (PD-1) showed an efficient antitumor effect. Thus, CD69 is an attractive target for cancer immunotherapy that synergizes with immune checkpoint blockade.

16 September 2024
Verified
Other
Open access
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
MKMotoko Kimura
Motoko Kimura
MKMasahiro Kiuchi
Masahiro Kiuchi
AAAmi Aoki
Ami Aoki
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes